NEVER a buyout. Anyone even entertaining numbers is either

New Post Public Reply Private Reply Replies (3) Message Board
dejavu 123kidc #34565
1,083
NEVER a buyout. Anyone even entertaining numbers is either a mole or extremely shortsighted. Why? Dividends....

https://www.dividend.com/dividend-stocks/heal...ction=desc

Quote:
AMGN
Amgen
Price: $234.53
Dividend: $6.40
Yield: 2.66%

GILD
Gilead Sciences
Price: $76.19
Dividend: $2.7200
Yield: 3.57%

TECH
Techne Corp
Price: $260.00
Dividend: $1.2800
Yield: 0.49%


Imagine, if you will, Leronlimab being SOC for JUST HIV. Only HIV.
Number of patients x Doses x Frequency.

What does that put the share price at?

How long does it take for CYDY to have more cash than it knows what to do with, and they declare a dividend?

How much will the dividend be?

Imagine it's $1.25 a year. What is your cost basis / PPS on your entry? Divide $1.25 by that, that would be your annual yield on those shares.

Multiply it by the number of shares you have... would it be nice to get that, every year?

What if the dividend is higher than $1.25 a year? What if it's $2.50? $5?

Where else are you going to get a guaranteed annual yield like that?

Now factor in CV19, cancers, ARDS, "ohm's list":
https://investorshangout.com/post/view?id=5723002

Quote:

An incomplete list of potential treatments targets for leronlimab.

Alzheimer's
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Coeliac Disease
Chronic Fatigue Syndrome
COPD
COVID-19 (and other corona viruses)
Crohn's Disease
Colitis
Dermatomyositis
Diabetes (type 1)
Duchenne Muscular Dystrophy (possibly other muscular dystrophys also)
Emphysema
Fibromyalgia
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Hepatitis (autoimmune)
HIV
Idiopathic Pulmonary Fibrosis
Inflammatory Bowel Disease
Influenza (severe)
Lambert-Eaton Syndrome
Lupus
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Neurofibromatosis
Parkinson's Disease
Pemphigus
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sickle Cell Disease (anti-inflammatory effect)
Sjogren’s Syndrome
Stroke
Tuberculosis
Vasculitis

Read More: https://investorshangout.com/post/view?id=572...z6MsG2xwS7


Sure, there will be capital gains for every indication Leronlimab is effective for. Those will be insane... a safe, easy to administer (subcutaneous / "insulin shot like" , easy to store and transport treatment for a whole slew of immune diseases and disorders....

But those gains get lost when another company siphons up the drug: Leronlimab's profits will go to prop up other (probably less significant / successful) projects, massive bloated advertising budgets, an army of middlemen and overpaid officers. If you think issuing a few million shares is dilution, try getting absorbed into a $20+ billion company when you're under $2 Billion.

So are the dividends. Poof!

Now, if anyone can tell me what opportunity on this planet is going to be better in the next 5-10 years... what is going to have capital gains like that and probably annual dividends like that, that you need a buyout to happen now so you can rush to make significantly better gains there..... if anyone can tell me what that opportunity is, I'll vote for a buyout at around a $50 billion valuation in the next two months.

If anyone can't... there's not a chance in h---.. NEVER a buyout.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 71

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
ACLM and eClinicalWorks Expand Lifestyle Medicine Reach

Updated Category News Views 92

Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...

Continue Reading
STVN's GLP-1 Fumble Sparks Shareholder Scrutiny

Updated Category News Views 35

The Storm Hits Stevanato: GLP-1 Blues Well, ain't this a fine pickle for Stevanato Group S.p.A. (NYSE:STVN). November 3, 2026, turned into quite the ride for those holding STVN shares. A tough third-quarter report dropped like a ton of bricks, driving the shares down after they coughed up a lower outlook for GLP-1 volumes in 2027. If you've been in the game long enough,...

Continue Reading
Tamagotchi Turns 30: Roblox Event Connects Worlds

Updated Category News Views 17

A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...

Continue Reading
ROBOTWORLD 2026: AI Reshapes Industrial Horizons

Updated Category News Views 48

A Grand Gathering of Robotics Minds Walking into KINTEX, Seoul's suburban behemoth of an exhibition center, you'll find a buzz that rivals the excitement of a stock floor on earnings day. It's ROBOTWORLD 2026, a stage set for tech titans and ambitious startups alike, all throwing in their chips on AI and robotics. From November 4th to 7th, 402 companies hailing from 17...

Continue Reading
3M's Huge Settlement: Navigating A Looming Legal Fog

Updated Category News Views 94

The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...

Continue Reading
DarioHealth Taps Palumbo to Drive Healthcare Evolution

Updated Category News Views 0

Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...

Continue Reading
VAB's Pharma Ad Guide: Emerging Trends and Insights

Updated Category News Views 191

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Continue Reading
SWFI's I20 Summit Spotlights 3,000 Promising Start-Ups

Updated Category News Views 101

Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...

Continue Reading
Compass Faces Securities Fraud Suit: Deadline Looms

Updated Category News Views 45

Compass's Legal Rumble: Shareholders Take Note You know there’s trouble when a firm’s every effort at glassy-eyed optimism is slapped with a lawsuit. We've seen this song and dance far too often, and now Compass, Inc. (NYSE: COMP) takes center stage. Schall, Brown & Schwartz LLP is rallying the troops for a knock-down-drag-out class action lawsuit, accusing Compass of...

Continue Reading
s of Cautious Optimism - Continue Reading" aria-label="Continue reading: Farmer Sentiment Rises, Hints of Cautious Optimism"> Continue Reading